324 related articles for article (PubMed ID: 10158460)
1. Potential savings from generic prescribing and generic substitution in South Africa.
Karim SS; Pillai G; Ziqubu-Page TT; Cassimjee MH; Morar MS
Health Policy Plan; 1996 Jun; 11(2):198-205. PubMed ID: 10158460
[TBL] [Abstract][Full Text] [Related]
2. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
Haas JS; Phillips KA; Gerstenberger EP; Seger AC
Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
[TBL] [Abstract][Full Text] [Related]
3. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
Murry L; Gerleman B; Urick B; Urmie J
J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
[TBL] [Abstract][Full Text] [Related]
4. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
5. Effect of fundholding and indicative prescribing schemes on general practitioners' prescribing costs.
Bradlow J; Coulter A
BMJ; 1993 Nov; 307(6913):1186-9. PubMed ID: 8251847
[TBL] [Abstract][Full Text] [Related]
6. Generic drug utilisation on the General Medical Services (GMS) scheme in 2001.
Tilson L; McGowan B; Ryan M; Barry M
Ir Med J; 2003 Jun; 96(6):176-9. PubMed ID: 12926759
[TBL] [Abstract][Full Text] [Related]
7. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
[TBL] [Abstract][Full Text] [Related]
8. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
[TBL] [Abstract][Full Text] [Related]
9. Generic drug prescriptions following hospital discharge: a prospective study in France.
Chu C; Rudant E; Bonvalet M; Agostini H; Cavalié P; Bonhomme-Faivre L; Frenkiel J; Taillandier J; Boissonnas A; Vittecoq D; Wyplosz B
Eur J Intern Med; 2011 Oct; 22(5):e45-9. PubMed ID: 21925042
[TBL] [Abstract][Full Text] [Related]
10. Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data.
Goldacre B; Reynolds C; Powell-Smith A; Walker AJ; Yates TA; Croker R; Smeeth L
BMJ Open; 2019 Feb; 9(2):e026886. PubMed ID: 30813120
[TBL] [Abstract][Full Text] [Related]
11. Case study of the effects of office-based generic drug sampling on antibiotic drug costs and first-line antibiotic prescribing ratios.
Conklin MH; Culley EJ; O'Donnell J
J Manag Care Pharm; 2009; 15(1):55-61. PubMed ID: 19125550
[TBL] [Abstract][Full Text] [Related]
12. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
[TBL] [Abstract][Full Text] [Related]
13. The association of insurance type with costs of dispensed drugs.
Mott DA; Kreling DH
Inquiry; 1998; 35(1):23-35. PubMed ID: 9597015
[TBL] [Abstract][Full Text] [Related]
14. Summaries for patients. Potential savings with substitution of generic drugs for brand-name drugs.
Ann Intern Med; 2005 Jun; 142(11):I30. PubMed ID: 15941691
[No Abstract] [Full Text] [Related]
15. Experience of a medicines reference-pricing model.
Rothberg AD; Blignault J; Serfontein CB; Valodia B; Eekhout S; Pels LM
S Afr Med J; 2004 Mar; 94(3):183-8. PubMed ID: 15098277
[TBL] [Abstract][Full Text] [Related]
16. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
Fischer MA; Avorn J
Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
[TBL] [Abstract][Full Text] [Related]
17. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
Counterweight Project Team
J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
[TBL] [Abstract][Full Text] [Related]
18. New mechanism to identify cost savings in English NHS prescribing: minimising 'price per unit', a cross-sectional study.
Croker R; Walker AJ; Bacon S; Curtis HJ; French L; Goldacre B
BMJ Open; 2018 Feb; 8(2):e019643. PubMed ID: 29439078
[TBL] [Abstract][Full Text] [Related]
19. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
20. Impact of brand drug discount cards on private insurer, government and patient expenditures.
Law MR; Chan FKI; Harrison M; Worthington HC
CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
